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Rationale for pneumococcal 
conjugate vaccine and 
rotavirus vaccine introduction 
into public immunisation 
programmes
While progress has been made in preventing deaths due to some 
of the vaccine-preventable diseases (e.g. measles deaths reduced 
from 535 000 in 2000 to 139 000 by 2010),[1] a greater proportion of 
vaccine-preventable deaths is now attributed to diseases for which 
there are under-utilised and/or newly developed vaccines, such as 
those against pneumococcal disease and rotavirus. Although these 
vaccines are widely used in developed and well-resourced countries, 
their use in middle- and lower-income countries has remained 
limited, mainly owing to the high costs of the vaccines.
Worldwide it was estimated that pneumococcal disease was 
responsible for 14 million severe cases and 830 000 deaths in 2000,[2] 
and that there were 7 million severe cases of rotavirus diarrhoea and 
453 000 deaths in 2004.[3] Significant declines in severe disease and/or 
mortality from these pathogens have been demonstrated in countries 
where the newer vaccines were introduced into public immunisation 
programmes.[4,5] In the absence of targeted vaccination, rotavirus 
remains the most common cause of severe diarrhoea (associated with 
28% of cases) and Streptococcus pneumoniae is still responsible for a 
high proportion (18.3%) of cases of severe pneumonia.[6] 
In 2007, the World Health Organization (WHO) recommended 
that countries with under-5 mortality rates of >50/1 000 live births, 
and with a high prevalence of HIV or conditions that increase the risk 
of pneumococcal disease, should prioritise the introduction of the 
7-valent pneumococcal conjugate vaccine (PCV-7) in their national 
immunisation programmes.[7] Similar recommendations for rotavirus 
were subsequently issued.[8] 
These global recommendations were premised in part by pivotal 
studies that had been undertaken in South Africa (SA). These 
included a study on a 9-valent PCV in which vaccine efficacy 
was established against vaccine-serotype invasive pneumococcal 
disease in HIV-uninfected (83%) and HIV-infected children not on 
antiretroviral therapy (ART) (63%), as well as against pneumonia in 
the first 2 years of life.[9] Also, a vaccine efficacy study on rotavirus 
vaccine (RV) observed 73% protection against rotavirus-associated 
severe diarrhoeal disease in the SA setting, with its high prevalence 
of HIV infection.[10] Although the efficacy study on RV was not 
specifically powered to evaluate for protection in HIV-infected 
children, the immunogenicity and safety of RV in this group had been 
established in a separate SA study.[11] 
Introduction of PCV and RV into the SA public 
immunisation programme
SA was the first country in Africa to introduce PCV and RV into its 
routine Expanded Programme on Immunization (EPI). PCV-7 was 
introduced in April 2009, followed by RV in August of the same year. The 
13-valent pneumococcal conjugate vaccine (PCV-13), estimated to confer 
a further 20% protection against invasive pneumococcal disease (IPD), 
replaced PCV-7 in May 2011.[7] The introduction of these vaccines into 
the SA EPI was particularly notable, this country having been classified 
as a middle-income country and therefore ineligible for external donor 
support from the Global Alliance for Vaccines and Immunization for 
procurement of these vaccines. Consequently in SA, where all healthcare 
for children is free of charge, government increased its budget allocation 
for the procurement of childhood vaccines from approximately R200 
million to R1.25 billion per annum. Implementation of the new vaccines 
(which are packaged as prefilled single-dose syringes) also required 
further investment for doubling cold-chain capacity at both depot and 
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facility level (personal communication – EPI, 
National Department of Health).
PCV and RV dosing schedule in SA
The EPI schedule, which includes RV and PCV, 
is available online (http://www.doh.gov.za). On 
the advice of the National Advisory Group for 
Immunization (NAGI), SA adopted a dosing 
schedule different to that recommended by 
the WHO at the time.[12] In contrast to the 
WHO schedule, which recommended that 
PCV be given at 6, 10 and 14 weeks,[7] the 
PCV dosing schedule used in SA is a primary 
series at 6 and 14 weeks of age and a booster 
dose at 9 months of age, aimed at possibly 
extending the duration of protection against 
IPD in HIV-infected children, who at the time 
of implementation accounted for two-thirds 
of cases.[13] This was decided upon to address 
specific observations of waning immunity 
among HIV-infected children noted in the 
SA PCV vaccine efficacy trial,[14] and also to 
manage logistical issues with the simultaneous 
introduction of PCV and RV into the EPI. 
The immunogenicity of the implemented PCV 
dosing schedule has since been confirmed 
in SA children, including demonstration 
of higher antibody concentrations after the 
third dose at age 9 months compared with 
administration at age 14 weeks in the 6-, 10- 
and 14-week dosing schedule recommended 
by the WHO.[15] 
The rationale for RV being incorporated as 
a 6- and 14-week schedule was premised upon 
attempting to induce at least partial immunity 
as early as possible, i.e. the first dose at age 
6 weeks rather than 10 weeks, while the 
decision to administer the second dose at 14 
weeks was based on assisting with training 
in and the logistics of implementation of the 
concurrent introduction of PCV and RV into 
the EPI. The immunogenicity of RV using the 
6- and 14-week schedule, including with the 
first dose being administered concurrently 
with the oral polio vaccine, has also been 
confirmed.[16]
Coverage with PCV and RV
The National Department of Health monitors 
the EPI programme performance using 
routine data submitted through the District 
Health Information System (DHIS). Coverage 
for a particular vaccine is calculated by 
dividing the number of doses that are reported 
to have been administered (predominantly in 
primary healthcare facilities) by the target 
population (based on mid-year population 
estimates published by Statistics South Africa 
and derived from census data).
The DHIS estimates for coverage with 
the third dose of PCV at 9 months of age 
increased from 10.4% in 2009 at the start 
of the PCV immunisation programme 
to 64.3% in 2010 and 99% in 2012 
(unpublished data – DHIS, extracted May 
2013) (Fig.  1). The >100% coverage rates 
observed in provinces such as Gauteng 
and Limpopo highlight the limitations of 
the DHIS as a tool for measuring vaccine 
coverage, probably resulting from inaccurate 
population denominators. Similarly, national 
coverage estimates for the second dose of 
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Fig. 1. District Health Information Systems estimates of coverage rates for the third dose of pneumococcal 
conjugate vaccine scheduled for administration at 9 months of age by province and nationally from 2009 
to 2012. (PVC = pneumococcal conjugate vaccine; EC = Eastern Cape; FS = Free State; GP = Gauteng; 
KZN = KwaZulu-Natal; LP = Limpopo; MP = Mpumalanga; NW = North West; NC = Northern Cape; 
WC = Western Cape; SA = South Africa).
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Fig. 2. District Health Information Systems estimates of coverage rates for the second dose of rotavirus 
vaccine administered at 14 weeks of age by province and nationally from 2009 to 2012. (RV = rotavirus 
vaccine; EC = Eastern Cape; FS = Free State; GP = Gauteng; KZN = KwaZulu-Natal; LP = Limpopo; 
MP = Mpumalanga; NW = North West; NC = Northern Cape; WC = Western Cape; SA = South Africa).
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Fig. 3. District Health Information Systems estimates of coverage rates for the third dose of hepatitis B 
vaccine administered at 14 weeks of age in South Africa from 2003 to 2012.
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RV administered at 14 weeks of age increased from 66.5% in 2010 to 
100.6% in 2012 nationally (Fig. 2). 
It should be noted that the DHIS reports high coverage for the 
traditional vaccines, e.g. coverage for the third dose of hepatitis B vaccine 
has been reported to be between 96% and 100% since 2005 (Fig.  3). 
These DHIS figures are not universally accepted as an accurate reflection 
of true coverage. For example, WHO/United Nations Children’s Fund 
(UNICEF) estimates for PCV third-dose coverage were 72% for 2011 
and 81% for 2012 (compared with DHIS figures of 89% and 98%, 
respectively), and 72% for 2011 and 78% for 2012 for the RV second dose 
(compared with DHIS figures of 78% and 100%, respectively).[17]
The differences in coverage estimates for the two new vaccines 
are smaller than the differences in coverage estimates for more 
traditional vaccines (e.g. for 2012 the WHO/UNICEF estimated 
coverage of the third dose of DTP to be 68% compared with a DHIS 
figure of 93%). This situation arises from the fact that WHO/UNICEF 
estimates of vaccine coverage are adjusted for differences in coverage 
rates between administrative reporting by government (i.e. DHIS 
figures in SA) and the actual coverage prevalence observed at the 
time of the last coverage survey undertaken in the country. In SA, 
the last representative population-based survey with immunisation 
coverage figures that were considered valid was undertaken in 1998. [18] 
However, the WHO/UNICEF use coverage data from the 2003 
Demographic and Health Survey,[19] which had limitations and did 
not produce reliable immunisation coverage figures. All subsequent 
WHO/UNICEF estimates have been adjusted downwards in line with 
the difference between administrative and survey estimates from 2003. 
A drawback of this methodology is that it is oblivious to any changes, 
e.g. strengthening or weakening of the EPI, which are likely to have 
occurred over more than a decade in a country like SA. Furthermore, 
WHO/UNICEF estimates are characterised by internal inconsistencies. 
For example, coverage estimates for the third doses of Haemophilus 
influenzae type b conjugate vaccine (HibCV) and diphtheria-tetanus 
(DTP) toxoid-whole cell pertussis (DTP combination vaccine) show 
considerable variation, despite the fact that the lyophilised HibCV is 
re-constituted with DTP in SA, so that the coverage for these vaccines 
should be identical. 
Unfortunately, in the absence of a recent high-quality immunisation 
coverage survey in SA, vaccine coverage remains uncertain. However, 
both the DHIS data and the WHO/UNICEF data suggest that 
coverage of the new vaccines had reached levels comparable with 
those of the traditional vaccines 2 years after introduction.
Effectiveness of PCV and RV in SA
SA should have been well suited to measure the impact of the 
introduction of PCV and RV in reducing under-5 morbidity and 
mortality, owing to the structure of the healthcare system. In 
particular, although there is a parallel private sector, the majority 
(>80%) of the population is cared for in the public health sector 
because of lack of private medical insurance coupled with the high 
cost of private care. Also, impediments to access to healthcare 
are addressed by free healthcare being provided to children <6 
years of age, including hospitalisation and immunisation services. 
Unfortunately weaknesses in the vital registration systems, including 
delays in availability of updated mortality data, coupled with a 
limited healthcare information system, pose a challenge to accurately 
quantifying the cost-benefit and impact of the introduction of these 
new vaccines into the public healthcare system. 
The usefulness of established and functional health information 
systems for demonstrating the impact of vaccines has been 
demonstrated in other middle-income countries such as Mexico, 
which has a similar gross domestic product and healthcare system 
to SA. The Mexican Ministry of Health electronic hospital registries 
show that RV reduced all-cause diarrhoea hospitalisation by 40%, 
and all-cause diarrhoea mortality declined by 35% following RV 
introduction.[20,21] Notably, such differences were evident in a diversity 
of socioeconomic settings in Mexico.[22] Similarly, electronic databases 
were used in the USA to demonstrate a 36% reduction in all-cause 
pneumonia hospitalisation in children <2 years of age within 3 - 4 
years of PCV introduction, an effect that was sustained even a 
decade after PCV introduction.[23] A number of other countries have 
also variably used available health data registries to measure the 
public health impact of PCV and RV on pneumonia and diarrhoea 
hospitalisation, respectively.
SA faces an additional challenge in understanding the impact of the 
introduction of PCV and RV in that this has taken place in parallel 
with changes in mother-to-child transmission (MTCT) of HIV 
programmes, as well as more effective management of HIV-infected 
children. Temporal trend data should therefore be interpreted in 
the context of these changes, which individually may impact on the 
incidence of pneumonia and diarrhoea as well as hospitalisation and 
mortality. In an effort to quantify the impact of the introduction 
of the two vaccines on child health and survival in SA, data from a 
number of sources were reviewed, and are summarised below.
Case-control studies on effectiveness of PCV and RV
Case-control studies have been undertaken to establish vaccine 
effectiveness for PCV and RV, to corroborate the results observed in 
the efficacy trials in SA. These have included studies to determine 
PCV vaccine effectiveness against pneumonia and IPD, as well as 
RV effectiveness against all-cause and rotavirus-associated diarrhoea 
hospitalisation. Using the case-control study design, a multi-centre 
study in SA reported that PCV vaccination was associated with 
a 69% (95% confidence interval (CI) 7 - 90) reduced odds of 
hospitalisation for vaccine-serotype IPD and a 46% (95% CI 0 - 71) 
lesser likelihood of hospitalisation for IPD due to any serotype in 
HIV-uninfected children older than 16 weeks of age.[24] However, the 
study failed to confirm PCV effectiveness against vaccine-serotype 
or overall IPD in HIV-infected children, despite having access 
to ART.[24] The reason for this remains unclear and has led to the 
NAGI recommending that HIV-infected children should receive 
an additional dose of PCV at 10 weeks of age (i.e. a 3+1 dosing 
schedule). The immune responses following two doses of PCV given 
at 6 and 10 weeks of age were, however, similar in HIV-infected 
SA infants on ART compared with HIV-uninfected SA infants.[25] 
Furthermore, provisional results of a case-control study also showed 
that PCV-immunised, HIV-uninfected children were 27% (95% CI 
0 - 49) less likely than unimmunised children to be hospitalised 
for presumed bacterial pneumonia.[26] A multi-centre, case-control 
study to evaluate the effectiveness of RV against rotavirus-associated 
diarrhoea hospitalisation is also nearing completion. 
Public health impact and surveillance data
While case-control studies are useful for measuring the direct 
effectiveness of the vaccines, they are less informative in helping us 
understand the public health impact of the vaccines. The latter is best 
captured by examining temporal trends in disease in conjunction 
with introduction of various interventions, such as vaccines. 
A limited number of ecological studies are underway in SA. These 
include a rotavirus surveillance study undertaken at sentinel hospital 
sites since 2009 that aims to measure the effectiveness of RV against 
diarrhoea hospitalisation.[27] The results from this study reported that, 
compared with 2009, there was a 60% (215 v. 534 cases) reduction in 
rotavirus diarrhoea hospitalisation in 2010 and a 64% (190 v. 534 cases) 
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reduction by 2011. Furthermore, there were 
also declines in hospitalisations for all-cause 
diarrhoea among infants, including a 34% 
(713/1 077) reduction in 2010 and a 31% 
(742/1 077) reduction by 2011, compared with 
2009. These data corroborate the findings of a 
review on the public health impact of RV in 
middle-income Latin American countries.[28] 
Observations from the review included that 
RV immunisation was associated with a 22 
- 41% reduction in gastroenteritis-associated 
mortality, a 17 - 51% reduction in all-cause 
gastroenteritis-associated hospitalisation, and 
a 59 - 81% reduction in rotavirus-specific 
gastroenteritis hospitalisation among children 
younger than 5 years of age.[28] 
Additionally, an ecological study is 
underway to establish the effectiveness of 
PCV against IPD, for which there has been 
surveillance for more than a decade before 
vaccine introduction in SA.[29,30] Provisional 
data up to the end of 2011, during which 
time 7-valent PCV was being used, showed 
a 79% reduction in vaccine-serotype IPD 
and a 28% decline in non-vaccine-serotype 
IPD in SA when comparing 2005 - 2008 
with 2011. [30] The greater decline in vaccine-
serotype IPD compared with non-vaccine-
serotype IPD suggests that while some of the 
decline may have been due to reduced MTCT 
of HIV and improved access to ART for 
HIV-infected children, PCV immunisation 
also contributed. Other studies underway 
in SA include an ecological study in Soweto, 
Johannesburg, with a population of ~1.25 
million people and an annual birth cohort 
of 29  000. This study aims to measure the 
effectiveness of PCV and RV immunisation 
on all-cause pneumonia and all-cause 
diarrhoea hospitalisation, which would 
provide more insight into the public health 
impact of immunisation with these vaccines, 
albeit in a limited geographical locality. 
Although a national health usage registry 
has not been established in SA, some data 
on hospitalisation and in-hospital mortality 
are available. Included among these sources 
are the DHIS and Child Healthcare Problem 
Identification Programme (Child PIP). The 
DHIS collates data that are routinely submitted 
by public healthcare facilities. Data on the 
incidence of pneumonia and diarrhoea with 
dehydration in children <5 years of age are 
collected. Furthermore, data on in-hospital 
case fatality rates among children <5 years 
of age admitted to public hospitals are also 
collected. While the completeness and quality 
of data collected through the DHIS have 
improved substantially over the past years, 
trends should nevertheless be interpreted with 
care. Based on the DHIS data on pneumonia 
and diarrhoea in children <5 years of age for 
the period 2007 - 2012, the incidences for 
both diarrhoea and pneumonia have shown 
a downward trend (Table  1). This includes a 
steady decline in the incidence of diarrhoea 
with dehydration from 2008 to 2009 compared 
with later years, including a 44% reduction 
by 2012. Furthermore, there was a decline in 
the incidence of pneumonia from ~96/1  000 
in 2008 - 2009 to 69.3/1 000 by 2012 (a 28% 
decrease) (Table 1). There has been an ~40% 
reduction in case fatality rates associated with 
diarrhoea and pneumonia (Table 1).
Another source of mortality data in public 
hospitals is available from Child PIP, a child 
mortality audit system that is increasingly 
being used in hospitals throughout SA. Data 
on the absolute number of under-5 deaths 
from acute diarrhoea and pneumonia, and 
the proportions of all deaths with which 
they are associated, from 41 hospitals that 
have consistently submitted data from 2008 
to 2012 are shown in Table  2. During 
this period, the number of deaths from 
diarrhoea has shown a steady decline, and 
was 56% lower in 2012 (N=244) than in 
2008 (N=556) (Table  2). Similarly, there 
has been a steady decline in deaths from 
pneumonia, which decreased by 53% 
between 2008 (N=692) and 2012 (N=326). 
The proportions of all under-5 deaths 
attributed to diarrhoea (19.4% in 2008 and 
16.2% in 2012) and pneumonia (24.2% in 
2008 and 21.6% in 2010 - 2012), while also 
showing a downward decline, nevertheless 
highlight the continuing contribution of 
these syndromes to under-5 mortality in 
SA (unpublished data, Medical Research 
Council, Child PIP, extracted 5 August). 
Analysis of a smaller number of hospitals 
(N=18) that have submitted complete data 
Table 1. District Health Information Systems data on diarrhoea and pneumonia in 
children <5 years of age at public health facilities, 2007 - 2012
2007 2008 2009 2010 2011 2012
Diarrhoea with dehydration incidence,  
per 1 000 children <5 years of age 
19.8 22.6 22.1 17.6 15.2 12.3
Pneumonia incidence,  
per 1 000 children <5 years of age
87.4 92.8 100.0 82.7 83.2 69.3
Diarrhoea case fatality rate,  
% of children <5 years of age admitted to hospital
8.4 8.8 7.3 7.0 5.2 4.2
Pneumonia case fatality rate,  
% of children <5 years of age admitted to hospital
8.4 9.3 6.5 6.3 4.3 4.1
Table 2. Deaths of children <5 years of age from acute diarrhoea and pneumonia at 
hospitals with 5 years of complete data (N=41), 2008 - 2012
Total deaths, N
Deaths from, n (% of N)
Acute diarrhoea Pneumonia
2008 2 863 556 (19.4) 692 (24.2)
2009 2 511 455 (18.1) 603 (24.0)
2010 2 251 392 (17.4) 487 (21.6)
2011 1 716 294 (17.1) 370 (21.6)
2012 1 507 244 (16.2) 326 (21.6)
Table 3. Deaths of children <5 years of age from acute diarrhoea and pneumonia at 
hospitals with 6 years of complete data (N=18), 2007 - 2012
Total deaths, N
Deaths from, n (% of N)
Acute diarrhoea Pneumonia
2007 1 426 189 (13.3) 259 (18.2)
2008 1 436 248 (17.3) 274 (19.1)
2009 1 177 204 (17.3) 245 (20.8)
2010 1 000 165 (16.5) 152 (15.2)
2011 748 123 (16.4) 145 (19.4)
2012 594 91 (15.3) 108 (18.2)
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for the period 2007 - 2012 showed an increase in the number of 
deaths from diarrhoea and pneumonia between 2007 and 2008, 
followed by declines (Table 3).
Although data on the HIV status of children who die are collected 
during the Child PIP mortality audit process, the incompleteness of 
data makes interpretation thereof difficult. Data on the HIV-infection 
status of children who died from pneumonia (from the 18 hospitals 
with complete data) are shown in Table 4. Despite the increase from 
2007 to 2012 in the percentage of children in whom HIV infection 
status was established at the time of their death, there has been a 
decline in the number of deaths involving HIV-infected children 
(from 80 in 2007 to 24 in 2012, a 70% reduction). In contrast, 
the number of deaths of children who were confirmed as being 
HIV-uninfected has remained steadier over this time, albeit with 
an increase in the number in whom HIV testing was undertaken. 
This would therefore also suggest a decline in deaths among HIV-
uninfected children between 2007 and 2012. 
Table  5 shows the number of children <5 years of age from 18 
hospitals whose deaths were attributed to diarrhoea (data from Child 
PIP). Similar to all-cause deaths, an increasing proportion of children 
who died of diarrhoea were tested for HIV infection in 2012 compared 
with earlier years; nevertheless, there was a trend towards a decline 
in diarrhoea deaths associated with HIV infection and among HIV-
uninfected children (Table 5). Importantly, the Child PIP database is 
not population denominator centred, and hence is unable to provide 
incidence trend data at a population level. Also, as the reporting is 
based on summary data for the hospitals instead of individual patient 
data, it is not amenable to being used to determine issues such as HIV-
stratified trends in incidence of diseases to help distinguish between 
the relative contribution of PCV and RV compared with changes in 
HIV management in reducing under-5 childhood mortality in SA.
Child mortality estimates
A significant decline (30%) in under-5 mortality has been observed in 
SA between 2006 and 2011. The United Nations estimates that under-
5 mortality declined from 75.8/1 000 live births in 2006 to 46.7/1 000 
live births in 2011,[32] and in addition there has been an estimated 48% 
reduction in diarrhoea-associated mortality and a 19% reduction in 
pneumonia mortality.[32] A major factor contributing to this decline in 
under-5 mortality has been a 47% reduction in deaths attributed to 
HIV/AIDS and related complications.[32] This accomplishment has been 
driven by improved management of HIV-infected children with ART 
since 2006, as well as improved coverage with a more aggressive ART 
regimen for pregnant women aimed at reducing MTCT of HIV. The 
rate of MTCT of HIV has declined from 9.6% in 2008, when mainly 
nevirapine was used for the prevention of MTCT, to approximately 2.8% 
with more aggressive ART regimens having been implemented. [33] The 
model used for estimating the causes of under-5 mortality attributes 
all deaths in HIV-infected children to AIDS, although the major direct 
causes of death in these children are similar to those in the general 
population, i.e. pneumonia and diarrhoea. The risks of morbidity and 
mortality from common childhood illnesses such as pneumonia and 
diarrhoea are, however, much increased in HIV-infected children. Prior 
to the widespread management of HIV-infected children with ART, the 
risks of hospitalisation for pneumonia and diarrhoea were 9-fold and 5.4-
fold greater, respectively, among HIV-infected than HIV-uninfected SA 
children.[34,35] Also, HIV-infected children in SA had a 40-fold greater risk 
of hospitalisation for invasive pneumococcal disease and an estimated 
2.3-fold increased risk of hospitalisation for rotavirus diarrhoeal disease 
than HIV-uninfected children.[35,36] Although improved access to ART has 
mitigated some of this risk, even in the era of ART HIV-infected children 
remain at a 20-fold greater risk of developing invasive pneumococcal 
disease.[37] Furthermore, even when ART was initiated early in HIV-
Table 5. HIV status of children <5 years of age who died from acute diarrhoea at hospitals with 6 years of complete data (N=18), 2007 - 2012
HIV-negative
n (%)
HIV-infected
n (%)
HIV-exposed*
n (%)
Unknown
n (%)
Total
N
2007 25 (13.2) 42 (22.2) 48 (25.4) 74 (39.2) 189
2008 30 (12.1) 72 (29.0) 68 (27.4) 78 (31.5) 248
2009 46 (22.5) 51 (25.0) 49 (24.0) 58 (28.4) 204
2010 41 (24.8) 46 (27.9) 51 (30.9) 27 (16.4) 165
2011 32 (26.0) 35 (28.5) 32 (26.0) 24 (19.5) 123
2012 31 (34.1) 29 (31.9) 18 (19.8) 13 (14.3) 91
Total, N 205 (20.1) 275 (27.0) 266 (26.1) 274 (26.9) 1 020
*HIV-exposed with unknown HIV status.
Table 4. HIV status of children <5 years of age who died from pneumonia at hospitals with 6 years of complete data (N=18), 2007 - 2012
HIV-negative
n (%)
HIV-infected
n (%)
HIV-exposed*
n (%)
Unknown
n (%)
Total
N
2007 30 (11.6) 80 (30.9) 75 (29.0) 74 (28.6) 259
2008 60 (21.9) 70 (25.5) 76 (27.7) 68 (24.8) 274
2009 54 (22.0) 49 (20.0) 87 (35.5) 55 (22.4) 245
2010 32 (21.1) 46 (30.3) 49 (32.2) 25 (16.4) 152
2011 53 (36.6) 39 (26.9) 28 (19.3) 25 (17.2) 145
2012 45 (41.7) 24 (22.2) 23 (21.3) 16 (14.8) 108
Total, N 274 (23.2) 308 (26.0) 338 (28.6) 263 (22.2) 1 183
*HIV-exposed with unknown HIV status.
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infected infants, pneumonia and diarrhoea 
were individually identified as the causes of 
death in one-third of HIV-infected children.[38] 
Extrapolating from the direct causes of 
death in SA children with HIV/AIDS, the 
imputed proportions of all under-5 mortality 
that could be attributed to pneumonia and 
diarrhoea in 2010 were ~19% (N≈11 000) and 
~15% (N≈9 000), respectively (Fig.  4). While 
further reduction in vertical transmission and 
improved ART management of HIV-infected 
children remain the mainstay of reducing HIV/
AIDS-associated morbidity and mortality, 
additional complementary interventions such 
as immunisation with new and under-utilised 
existing vaccines would contribute further 
towards reducing morbidity and mortality in 
this high-risk group.  
Conclusion
SA has demonstrated a clear commitment 
to reducing child mortality and to ensuring 
universal access to life-saving vaccines 
by being at the forefront in introducing 
new vaccines such as PCV and RV into its 
childhood EPI. While exact coverage levels 
remain contested, coverage with the new 
vaccines has been scaled up rapidly to levels 
comparable to those of traditional vaccines. 
The uncertainty around immunisation 
coverage remains a serious challenge, and 
in the absence of a recent high-quality 
survey in SA, vaccine coverage remains 
uncertain. This limits government’s ability 
to accurately monitor and improve EPI 
performance. Furthermore, the WHO and 
UNICEF will not change their estimates 
of SA’s coverage figures until a valid 
coverage survey is conducted, as they rely 
on recent coverage surveys to produce 
country coverage estimates and will not 
use only administrative figures reported by 
a country. 
The effects of these new vaccines on under-5 
childhood morbidity and mortality in SA 
are challenging to measure with existing 
data sources. Overall child mortality rates 
have declined substantially in the past 5 
years, while data from a number of sources 
show substantial declines in the incidence of 
diarrhoea with dehydration and pneumonia, 
as well as in hospitalisations and deaths from 
diarrhoea and pneumonia. However, since 
pneumonia and diarrhoea are also leading 
causes of death in HIV-infected children, 
the relative impact of improvements in HIV 
prevention and management is difficult to 
disentangle from the decline in pneumonia 
and diarrhoea morbidity and mortality due 
to the introduction of the vaccines. The 
reduction in diarrhoea mortality may at 
least in part be related to improved access 
to tapped potable water, which has been 
associated with significant global reductions 
in deaths from diarrhoea, and specifically 
diarrhoea caused by bacteria.[39] 
As HIV-associated child mortality declines, 
further child survival gains will depend 
increasingly on preventing deaths among 
HIV-uninfected children. The reductions 
in hospitalisation of HIV-uninfected infants 
demonstrated in the case-control studies 
suggest that these vaccines will play an 
increasing role in preventing child morbidity 
and mortality in the future.
Further challenges in addressing the 
effectiveness of PCV and RV immunisation 
in SA relate to the lack of electronic hospital 
registries, which would make measurement of 
the impact of PCV and RV on mortality and 
morbidity much simpler. 
It is strongly recommended that a high-
quality immunisation coverage survey 
be conducted in every district and that an 
electronic hospital registry be implemented in 
SA. This would assist in better understanding 
of whether the substantial investment in 
vaccine procurement is translating into a 
benefit, particularly in impoverished districts 
and communities. 
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